https://the483.com/openai-gpt55-api-pricing/ The 483 en 2026-04-24T20:06:35.399Z OpenAI Priced GPT-5.5 at $30/1M Output, Pro at $180 https://the483.com/maine-ld2082-ai-therapy-banned/ The 483 en 2026-04-24T20:06:01.569Z Banned: Maine LD 2082 Makes AI Therapy Illegal as More Than Ten States Follow https://the483.com/anthropic-aws-100b-amazon-deal/ The 483 en 2026-04-24T20:05:53.935Z Amazon Locks Anthropic Into Over $100B AWS Deal, Adds $5B https://the483.com/google-a2a-enterprise-standard/ The 483 en 2026-04-24T20:04:29.417Z Google Rewires Enterprise AI Stack With A2A Protocol at 150 Organizations https://the483.com/google-anthropic-40b-bet/ The 483 en 2026-04-24T20:03:15.438Z Google Commits $40B to Anthropic at $380B Valuation https://the483.com/vercel-context-ai-oauth-breach/ The 483 en 2026-04-24T20:02:36.169Z Vercel Loses Customer API Keys in Context AI Supply Chain Attack https://the483.com/kailera-record-ipo-hengrui-glp1/ The 483 en 2026-04-24T16:25:29.000Z Kailera Raises Record $625M IPO on Hengrui GLP-1 Pipeline https://the483.com/regeneron-mfn-deal-17-companies/ The 483 en 2026-04-24T15:31:18.000Z Regeneron Closes MFN Deal, Completing 17-Company White House Sweep https://the483.com/china-ai-distillation-theft-crackdown/ The 483 en 2026-04-24T14:38:16.000Z Prosecute China for AI Model Theft, Congress Tells State Department https://the483.com/regeneron-otarmeni-mfn-deal/ The 483 en 2026-04-24T13:49:13.545Z FDA Cleared Regeneron's Otarmeni; Last Big Pharma Signs MFN Deal https://the483.com/secure-data-act-illinois-bipa-preemption/ The 483 en 2026-04-24T03:11:32.000Z Filed: H.R. 8413 Could Preempt Illinois BIPA, California's Delete Act https://the483.com/amneal-kashiv-1b-biosimilar-deal/ The 483 en 2026-04-24T01:39:26.000Z Bought for $1.1B: Amneal Gets Kashiv and Its $56B Biosimilar Pipeline https://the483.com/amneal-biosimilar-375m-deal/ The 483 en 2026-04-24T00:47:20.000Z Amneal Buys Biosimilar Maker for $375M Upfront https://the483.com/regeneron-otarmeni-free-gene-therapy-hearing/ The 483 en 2026-04-23T23:21:02.000Z FDA Cleared Regeneron's $0 Gene Therapy for Rare Hearing Loss https://the483.com/regeneron-otarmeni-hearing-loss/ The 483 en 2026-04-23T22:19:23.000Z FDA Clears Regeneron's Otarmeni, First Gene Therapy for Inherited Hearing Loss https://the483.com/abbvie-14b-durham-campus/ The 483 en 2026-04-23T17:35:37.000Z AbbVie Builds $1.4B Durham Campus, First in North Carolina https://the483.com/new-life-pharma-glp1-inspection-warning/ The 483 en 2026-04-23T16:39:00.000Z FDA Warns New Life Pharma After GLP-1 Inspection Refusal https://the483.com/sqm-sec-fcpa-probe-resumed/ The 483 en 2026-04-23T15:40:00.000Z Fined $30.5M in 2017, SQM Now Faces Resumed SEC FCPA Probe https://the483.com/merck-google-1b-ai-deal/ The 483 en 2026-04-23T14:51:34.000Z Cut $1B Google Cloud Deal, Merck Targets HCP Engagement https://the483.com/ionis-zilganersen-alexander-disease-fda/ The 483 en 2026-04-23T12:29:03.000Z Ionis Filed Zilganersen for Sept. 22 FDA Decision; First AxD Drug https://the483.com/amneal-kashiv-1b-biosimilar-buyout/ The 483 en 2026-04-23T03:11:09.000Z Buys Kashiv for $1.1B, Amneal Eyes $200B Biosimilar Market https://the483.com/forager-repay-1b-takeover/ The 483 en 2026-04-23T01:38:59.000Z Forager Bids $1B for Repay at 75% Premium https://the483.com/lilly-kelonia-7b-gene-delivery/ The 483 en 2026-04-23T00:51:19.000Z Paid $7B for Kelonia, Lilly Bets on In Vivo Gene Delivery https://the483.com/smartmatic-fcpa-indictment-dismissal/ The 483 en 2026-04-22T22:19:55.000Z Smartmatic Fights First Corporate FCPA Indictment Since 2010